Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Pediatric Cancer

Chicago, IL—Approximately 25% of children, adolescents, and young adults with advanced cancer were eligible for a targeted therapy after genotyping of their tumors in the Pediatric Molecular Analysis for Therapy Choice (MATCH) clinical trial. That rate is more than double the 10% that researchers had projected.

Paige Johnson, DNP, CPNP, CPHON, discusses some of the characteristics that contribute to poor prognosis in infants with acute lymphoblastic leukemia, the results of clinical trials evaluating newer therapies to treat the disease, and what the future holds in terms of novel strategies.

“Considering the frequency of both pediatric cancer survivorship and of late toxicities related to treatment, childhood cancer is often the cancer diagnosis that lasts a lifetime,” said Kerry Parsons, PharmD.

Results 1 - 3 of 3